Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1977 1
1978 1
1980 1
1982 2
1983 1
1984 1
1985 3
1986 3
1987 2
1988 2
1989 8
1990 7
1991 4
1992 4
1993 9
1994 4
1995 3
1996 7
1997 6
1998 9
1999 9
2000 9
2001 18
2002 8
2003 15
2004 11
2005 11
2006 7
2007 10
2008 13
2009 11
2010 18
2011 23
2012 26
2013 19
2014 21
2015 33
2016 25
2017 37
2018 37
2019 31
2020 36
2021 32
2022 18
2023 16
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

507 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Breast Ductal Carcinoma In Situ, Low Grade"
Page 1
Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, Weaver DL, Winchester DJ, Hortobagyi GN. Giuliano AE, et al. CA Cancer J Clin. 2017 Jul 8;67(4):290-303. doi: 10.3322/caac.21393. Epub 2017 Mar 14. CA Cancer J Clin. 2017. PMID: 28294295 Free article.
The panel recognized the need to incorporate biologic factors, such as tumor grade, proliferation rate, estrogen and progesterone receptor expression, human epidermal growth factor 2 (HER2) expression, and gene expression prognostic panels into the staging system. . …
The panel recognized the need to incorporate biologic factors, such as tumor grade, proliferation rate, estrogen and progesterone rec …
The Clinical Utility of DCISionRT() on Radiation Therapy Decision Making in Patients with Ductal Carcinoma In Situ Following Breast-Conserving Surgery.
Shah C, Bremer T, Cox C, Whitworth P, Patel R, Patel A, Brown E, Gold L, Rock D, Riley L, Kesslering C, Brown S, Gabordi R, Pellicane J, Rabinovich R, Khan S, Templeton S, Majithia L, Willey SC, Wärnberg F, Gerber NK, Shivers S, Vicini FA. Shah C, et al. Ann Surg Oncol. 2021 Oct;28(11):5974-5984. doi: 10.1245/s10434-021-09903-1. Epub 2021 Apr 5. Ann Surg Oncol. 2021. PMID: 33821346 Free PMC article.
BACKGROUND: The role of radiation therapy (RT) following breast-conserving surgery (BCS) in ductal carcinoma in situ (DCIS) remains controversial. Trials have not identified a low-risk cohort, based on clinicopathologic features, who do not bene …
BACKGROUND: The role of radiation therapy (RT) following breast-conserving surgery (BCS) in ductal carcinoma in situ …
Hypofractionated Versus Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma In Situ in a Randomized Phase III Trial: The DBCG HYPO Trial.
Offersen BV, Alsner J, Nielsen HM, Jakobsen EH, Nielsen MH, Krause M, Stenbygaard L, Mjaaland I, Schreiber A, Kasti UM, Overgaard J; Danish Breast Cancer Group Radiation Therapy Committee. Offersen BV, et al. J Clin Oncol. 2020 Nov 1;38(31):3615-3625. doi: 10.1200/JCO.20.01363. Epub 2020 Sep 10. J Clin Oncol. 2020. PMID: 32910709 Clinical Trial.
PATIENTS AND METHODS: One thousand eight hundred eighty-two patients > 40 years of age who underwent breast-conserving surgery for node-negative breast cancer or ductal carcinoma in situ (DCIS) were randomly assigned to radiotherapy at a dose …
PATIENTS AND METHODS: One thousand eight hundred eighty-two patients > 40 years of age who underwent breast-conserving surgery for …
Ductal Carcinoma In Situ - Quo Vadis?
Peltecu G. Peltecu G. Chirurgia (Bucur). 2021 Dec;116(5 Suppl):S5-S6. Chirurgia (Bucur). 2021. PMID: 34967322 Free article. Review.
It is estimated that in the United States the incidence of DCIS, each year, varies between 18 to 25% of the total number of newly diagnosed breast cancers (4,5). Ductal carcinoma in situ belongs, genetically and pathomorphologically, to a heterogenous …
It is estimated that in the United States the incidence of DCIS, each year, varies between 18 to 25% of the total number of newly diagnosed …
Neuroendocrine Tumors of the Breast.
Visscher DW, Yasir S. Visscher DW, et al. Endocr Pathol. 2017 Jun;28(2):121-127. doi: 10.1007/s12022-017-9477-4. Endocr Pathol. 2017. PMID: 28389994 Review.
Solid papillary carcinoma is an intrinsically low grade/favorable prognosis class of breast neoplasia that usually presents in post-menopausal age groups. About half of solid papillary carcinoma present as a distinctive pattern of duct …
Solid papillary carcinoma is an intrinsically low grade/favorable prognosis class of breast neoplasia tha …
Duct carcinoma in situ: A personal perspective.
Lagios MD. Lagios MD. Breast J. 2020 Jun;26(6):1132-1137. doi: 10.1111/tbj.13860. Epub 2020 May 10. Breast J. 2020. PMID: 32390260 Review.
Such interventions do impact the frequency of contralateral occult in situ and invasive lesions. In the one study which permitted a comparison of local recurrence in irradiated vs nonirradiated breast, there was no added benefit of Tamoxifen in irradiated breasts. S …
Such interventions do impact the frequency of contralateral occult in situ and invasive lesions. In the one study which permitted a c …
Morphologic and Molecular Features of Breast Ductal Carcinoma in Situ.
Sanati S. Sanati S. Am J Pathol. 2019 May;189(5):946-955. doi: 10.1016/j.ajpath.2018.07.031. Epub 2018 Oct 29. Am J Pathol. 2019. PMID: 30385094 Free article. Review.
Ductal carcinoma in situ (DCIS) encompasses a highly heterogeneous group of lesions that differ with regard to their clinical presentations, histologic features, biomarker profiles, genetic abnormalities, and potential for progression. ...On the molecular lev …
Ductal carcinoma in situ (DCIS) encompasses a highly heterogeneous group of lesions that differ with regard to their cl …
DCIS: Risk Assessment in the Molecular Era.
Knowlton CA, Jimenez RB, Moran MS. Knowlton CA, et al. Semin Radiat Oncol. 2022 Jul;32(3):189-197. doi: 10.1016/j.semradonc.2022.01.005. Semin Radiat Oncol. 2022. PMID: 35688517 Review.
Ductal carcinoma in situ (DCIS) represents 20% of all breast cancers. ...RT after BCS reduces the risk of in-breast recurrence, decreasing subsequent in-situ and invasive cancers by 50%, with 10-year breast-cancer specific survival …
Ductal carcinoma in situ (DCIS) represents 20% of all breast cancers. ...RT after BCS reduces the risk of in- …
Treatment of low-risk ductal carcinoma in situ: is nothing better than something?
Benson JR, Jatoi I, Toi M. Benson JR, et al. Lancet Oncol. 2016 Oct;17(10):e442-e451. doi: 10.1016/S1470-2045(16)30367-9. Lancet Oncol. 2016. PMID: 27733270 Review.
Although adjuvant treatments might be withheld for low-risk lesions, surgical treatments incur potential morbidity, especially when mastectomy and breast reconstruction are done for widespread low-grade or intermediate-grade ductal car …
Although adjuvant treatments might be withheld for low-risk lesions, surgical treatments incur potential morbidity, especially when m …
Ductal carcinoma in situ: a disease entity that merits more recognition.
Dereere E, Papadimitriou K, Tjalma W, Altintas S. Dereere E, et al. Minerva Chir. 2015 Aug;70(4):231-9. Epub 2015 Apr 28. Minerva Chir. 2015. PMID: 25916193 Review.
Ductal carcinoma in situ (DCIS) is a non-invasive breast carcinoma that remains in the milk ducts. ...Risk factors for the development of ductal carcinoma in situ are: low parity, late age at first birth and menopause …
Ductal carcinoma in situ (DCIS) is a non-invasive breast carcinoma that remains in the milk ducts. ...Ris …
507 results